Literature DB >> 17122996

Reconstituted botulinum type A neurotoxin: clinical efficacy after long-term freezing before use.

Alan A Parsa1, Kevin D Lye, Fereydoun Don Parsa.   

Abstract

Botulinum neurotoxin type A (BoNT/A) is injected into muscles of facial expression for treatment of facial wrinkles. Manufacturers' recommendations state that the product should be used within 4 h of reconstitution to prevent loss of effectiveness. A prospective study was undertaken to evaluate the effectiveness of reconstituted BoNT/A when preserved in a frozen state for up to 6 months, as compared with nonfrozen BoNT/A used within 4 h after reconstitution. Treatment of 118 sites in 80 patients was performed and evaluated for aesthetic efficacy. Excellent results were observed in 94.8% of sites treated with nonfrozen BoNT/A and in 93.3% of the sites treated with frozen and thawed BoNT/A (p = 1). Minor side effects were rare and transient in both groups. In contrast to common belief, reconstituted BoNT/A may be frozen, thawed, and injected without losing its potency for up to 6 months, with efficacy equivalent to that of freshly prepared BoNT/A.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17122996     DOI: 10.1007/s00266-006-0161-1

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  4 in total

Review 1.  Comparison and overview of currently available neurotoxins.

Authors:  Thomas J Walker; Steven H Dayan
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

2.  Botulinum toxin in masticatory muscles: short- and long-term effects on muscle, bone, and craniofacial function in adult rabbits.

Authors:  Katherine L Rafferty; Zi Jun Liu; Wenmin Ye; Alfonso L Navarrete; Thao Tuong Nguyen; Atriya Salamati; Susan W Herring
Journal:  Bone       Date:  2011-12-02       Impact factor: 4.398

3.  Botulinum toxin type-A in the treatment of glabellar lines.

Authors:  Leslie Winter; Jeffrey Spiegel
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-12-22

Review 4.  Botulinum toxin in cancer therapy-current perspectives and limitations.

Authors:  Tomasz Grenda; Anna Grenda; Paweł Krawczyk; Krzysztof Kwiatek
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-24       Impact factor: 4.813

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.